证券代码：600855 证券简称：航天长峰 公告编号：2025-043 北京航天长峰股份有限公司（以下简称"航天长峰"或"公司") 根据实际工作需要，对公司电子邮箱进行变更，具体情况如下： 变更前的公司电子邮箱：db@casic.com.cn 变更后的公司电子邮箱：htcf_600855@163.com 除上述变更外，公司办公地址、联系电话等其他联系方式保持不 变。变更后的电子邮箱自本公告披露之日起正式启用，原邮箱地址同 步停用，敬请广大投资者注意。由此给投资者带来的不便，敬请谅解。 欢迎广大投资者通过新的电子邮箱与公司沟通交流。 特此公告。 北京航天长峰股份有限公司 北京航天长峰股份有限公司 关于变更公司电子邮箱的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 董事会 2025 年 8 月 26 日 ...

北京航天长峰股份有限公司关于与 航天科工财务有限责任公司开展 关联交易事项的持续风险评估报告 根据《上海证券交易所上市公司自律监管指引第 5 号——交易与 关联交易》的要求，北京航天长峰股份有限公司(以下简称"公司") 通过查验航天科工财务有限责任公司（以下简称"财务公司"）《金 融许可证》《企业法人营业执照》等证件资料，并审阅了财务公司资 产负债表、利润表、现金流量表等财务报表，对财务公司的经营资质、 业务和风险状况进行了评估，现将风险评估情况报告如下： 一、财务公司基本情况 航天科工财务有限责任公司经原中国银行保险监督管理委员会 批准（金融许可证编号：L0009H211000001）、北京市市场监督管理 局登记注册（统一社会信用代码：911100007109288907）的非银行金 融机构，依法接受相关监管机构的监督管理。 注册资本：438,489 万元人民币 法定代表人：王厚勇 注册地址：北京市海淀区紫竹院路 116 号 B 座 6 层、12 层 成立日期：2001 年 10 月 10 日 财务公司在监管机构核准的经营范围内开展业务，目前，经营范 围主要包括：对成员单位办理财务和融资顾问、信用鉴证及相关 ...

证券代码：600855 证券简称：航天长峰 公告编号：2025-046 北京航天长峰股份有限公司 关于部分募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京航天长峰股份有限公司（以下简称"公司"或"航天长峰"）于 2025 年 8 月 22 日分别召开了十二届二十次董事会会议和 2025 年第四次董事会审计委 员会会议，审议通过了《北京航天长峰股份有限公司关于部分募集资金投资项目 延期的议案》，同意对公司募集资金投资项目（以下简称"募投项目"）"基于 人工智能的侦测装备研制和系统平台研发及产业化项目"达到预计可使用状态日 期由原计划的 2026 年 4 月延后至 2027 年 4 月。本次延期未改变募投项目的实施 主体、实施方式、实施地点、资金用途、投资总额和投资项目内容，不会对募投 项目的实施造成实质性影响。具体情况如下。 一、募集资金基本情况 经中国证券监督管理委员会下发的《关于核准北京航天长峰股份有限公司非 公开发行股票的批复》（证监许可〔2022〕2375 号）核准，公司以非公开发行 的方 ...

证券代码：600855 证券简称：航天长峰 公告编号：2025-045 北京航天长峰股份有限公司 关于 2025 年半年度募集资金 存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证监会发布的《上市公司监管指引第 2 号——上市公司 募集资金管理和使用的监管要求》（证监会公告[2022]22 号）和《上 海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》等有关规定，北京航天长峰股份有限公司（以 下简称"公司"或"本公司"）编制了截至 2025 年 06 月 30 日的《关 于公司 2025 年半年度募集资金存放与实际使用情况的专项报告》。 一、募集资金基本情况 2022 年 10 月 8 日经中国证券监督管理委员会证监许可字 [2022]2375 号《关于核准北京航天长峰股份有限公司非公开发行股 票的批复》的核准，公司向特定对象发行人民币普通股 2,775.2474 万股，募集资金总额 32,525.90 万元，扣除承销费用、中介服务费等 费用后为 3 ...

Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of the year, primarily due to a challenging external market environment and intense industry competition [1] Financial Performance - The company achieved an operating revenue of 358 million yuan, which represents a decrease compared to the same period last year [1] - The net profit attributable to shareholders was -56 million yuan, indicating a loss and a decline from the previous year [1] Business Segment Analysis - The military infrared optoelectronic business experienced a reduction in order volume for traditional airborne products, leading to a decline in overall business scale and profit margins [1] - Other infrared optoelectronic products and airport bird control products have not yet achieved bulk sales, contributing to the overall performance decline [1] - The high-end medical equipment business did not meet market expansion expectations, resulting in low product sales volume and insufficient revenue support [1]

[Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) The company's board of directors and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, which is unaudited, and declare no profit distribution plan or non-operating fund occupation by controlling shareholders - The board of directors and senior management guarantee the truthfulness, accuracy, and completeness of the report, and assume legal responsibility[3](index=3&type=chunk) - This semi-annual report is unaudited[5](index=5&type=chunk) - The company's responsible person, chief accountant, and head of accounting department declare the financial report is true, accurate, and complete[5](index=5&type=chunk) - There is no profit distribution plan or capital reserve to share capital increase plan[6](index=6&type=chunk) - Forward-looking statements do not constitute substantive commitments, and investors are advised to pay attention to investment risks[6](index=6&type=chunk)[7](index=7&type=chunk) - There is no non-operating occupation of funds by controlling shareholders or other related parties[7](index=7&type=chunk) - There are no external guarantees provided in violation of decision-making procedures[7](index=7&type=chunk) [Section I Definitions](index=4&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) This section defines key terms and related parties used in the report, including the company's full name, abbreviation, legal representative, contact information, and major affiliates - Company's Chinese name: Beijing Aerospace Changfeng Co., Ltd., abbreviation: Aerospace Changfeng[13](index=13&type=chunk) - The company's legal representative: Xiao Haichao[13](index=13&type=chunk) - Board Secretary: Wang Yanbin (acting), contact number: (010)68385288[14](index=14&type=chunk) - Major related parties include China Aerospace Science and Industry Corporation Limited, China Aerospace Science and Industry Defense Technology Research Institute, etc[16](index=16&type=chunk) [Section II Company Profile and Key Financial Indicators](index=4&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section provides the company's basic information, contact details, stock overview, and key accounting data and financial indicators for the reporting period, showing a decline in revenue and net profit - Company stock abbreviation: Aerospace Changfeng, stock code: 600855, listed on: Shanghai Stock Exchange[19](index=19&type=chunk) 2025 H1 Key Accounting Data | Indicator | Amount (CNY) | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 357,818,810.76 | -26.62 | | Total Profit | -58,221,603.02 | Not Applicable | | Net Profit Attributable to Shareholders of Listed Company | -55,590,962.31 | Not Applicable | | Net Cash Flow from Operating Activities | -133,913,722.33 | Not Applicable | | Net Assets Attributable to Shareholders of Listed Company (Period-end) | 1,553,229,358.56 | -3.49 | | Total Assets (Period-end) | 3,674,362,149.00 | -1.28 | | Total Share Capital (Period-end) | 468,542,728.00 | - | 2025 H1 Key Financial Indicators | Indicator | Current Period | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (CNY/share) | -0.1186 | -0.1098 | Not Applicable | | Diluted Earnings Per Share (CNY/share) | -0.1186 | -0.1098 | Not Applicable | | Basic EPS after Deducting Non-recurring Gains and Losses (CNY/share) | -0.1305 | -0.1139 | Not Applicable | | Weighted Average Return on Net Assets (%) | -3.52 | -2.85 | Decreased by 0.67 percentage points | | Weighted Average Return on Net Assets after Deducting Non-recurring Gains and Losses (%) | -3.87 | -2.95 | Decreased by 0.92 percentage points | - Performance decline primarily due to reduced orders in military electronics infrared optoelectronic business and slower-than-expected market expansion in high-end medical equipment business[23](index=23&type=chunk) - Total non-recurring gains and losses amounted to **CNY 5.57 million**[26](index=26&type=chunk) [Section III Management Discussion and Analysis](index=7&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section details the company's operating performance during the reporting period, including industry, main businesses, operating results, core competitiveness, and risks, highlighting strategic adjustments and increased investment in market development and technological innovation - The company's main businesses are divided into three segments: military electronics, public safety, and high-end medical equipment, serving as a domestic high-end product R&D and manufacturer and a complex large-scale system planner and integrator[29](index=29&type=chunk) - During the reporting period, the company achieved operating revenue of **CNY 358 million** and net profit attributable to shareholders of **CNY -56 million**, both declining compared to the same period last year[30](index=30&type=chunk) - Performance loss primarily due to reduced orders in the traditional airborne military infrared optoelectronic business and new products not yet achieving mass sales, coupled with insufficient revenue support from the high-end medical equipment business due to slower-than-expected market expansion[30](index=30&type=chunk) - The company adheres to strategic leadership, focuses on its core businesses, plans for new security and low-altitude industries, continuously optimizes its industrial and asset structure, and precisely allocates resources[31](index=31&type=chunk) - New contract value for military electronics special module power business increased by **29.54%** year-on-year[31](index=31&type=chunk) - New contract value for the public safety industry increased by **38.89%** year-on-year, with improving operating performance[23](index=23&type=chunk) - In the high-end medical equipment business, ECMO product R&D, trial production, and marketing are steadily progressing, and the supporting air-oxygen blender has obtained medical device registration approval[31](index=31&type=chunk) - The company continues to increase investment in technological innovation, building a "two cores and one pillar" strategy, focusing on product development and layout in new-generation information technology, artificial intelligence, low-altitude economy, and new security fields[32](index=32&type=chunk) Major Financial Statement Item Changes | Item | Current Period Amount (CNY) | Prior Year Period Amount (CNY) | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 357,818,810.76 | 487,625,861.08 | -26.62 | | Operating Cost | 266,138,520.39 | 359,529,700.39 | -25.98 | | Selling Expenses | 39,470,688.49 | 52,450,191.81 | -24.75 | | Administrative Expenses | 87,776,234.96 | 93,062,610.10 | -5.68 | | Financial Expenses | 385,009.01 | 199,116.78 | 93.36 | | R&D Expenses | 32,504,656.62 | 38,420,436.41 | -15.40 | | Net Cash Flow from Operating Activities | -133,913,722.33 | -51,597,834.98 | Not Applicable | | Net Cash Flow from Investing Activities | -6,746,518.35 | -40,002,018.65 | Not Applicable | | Net Cash Flow from Financing Activities | -30,830,794.98 | -56,916,526.05 | Not Applicable | - Notes receivable at period-end decreased by **52.05%** compared to the end of the previous year, mainly due to matured acceptances and non-recourse commercial bill discounting[37](index=37&type=chunk) - Prepayments at period-end increased by **136.02%** compared to the end of the previous year, primarily due to increased investment in public safety business projects[37](index=37&type=chunk)[38](index=38&type=chunk) - Development expenditures at period-end increased by **115.61%** compared to the end of the previous year, mainly due to increased investment in capitalized projects[38](index=38&type=chunk) - The company's restricted assets at period-end amounted to **CNY 66.64 million**, mainly comprising funds frozen due to litigation, bank acceptance bill deposits, performance bonds, and letter of guarantee deposits[38](index=38&type=chunk) - The company plans to transfer its **55.45%** equity in Aerospace Burke (Guangdong) Technology Co., Ltd[42](index=42&type=chunk) Financial Data of Major Holding and Participating Companies (CNY in 10,000s) | Company Name | Total Assets | Net Assets | Operating Revenue | Operating Profit | Net Profit | | :--- | :--- | :--- | :--- | :--- | :--- | | Changfeng Technology | 113,803.44 | 3,495.77 | 12,248.12 | -154.80 | -167.60 | | Changfeng Kewei | 53,368.08 | 25,671.07 | 3,123.91 | -2,456.79 | -2,287.95 | | Aerospace Chaoyang Power | 97,149.96 | 67,855.09 | 13,835.36 | 2,430.18 | 2,219.34 | | Aerospace Burke | 34,632.76 | 19,271.71 | 5,514.51 | -318.06 | -290.35 | | Changfeng Medical | 16,450.83 | 12,184.31 | 418.67 | -1,532.36 | -1,532.36 | - The company faces risks of intensified market competition, insufficient technological innovation, and business transformation and upgrading, and has formulated corresponding countermeasures[45](index=45&type=chunk)[46](index=46&type=chunk)[47](index=47&type=chunk) [Section IV Corporate Governance, Environment, and Social Responsibility](index=14&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) This section discloses changes in the company's directors, supervisors, and senior management, profit distribution plan, equity incentive plan, environmental information, and rural revitalization efforts, highlighting management adjustments with the resignation of Mr. Su Zihua and the appointment of Mr. Liu Dajun as president and director - Mr. Su Zihua resigned from his positions as company director and president due to work changes[50](index=50&type=chunk) - Mr. Liu Dajun was appointed as the company's president and elected as a company director[50](index=50&type=chunk) - Mr. Liu Dajun resigned from his positions as company vice president and board secretary due to work changes, and Mr. Wang Yanbin, vice president, is acting as board secretary[51](index=51&type=chunk) - The proposed semi-annual profit distribution plan is "No," with no distribution or capitalization[52](index=52&type=chunk) - The company actively responded to the call for "consolidating and expanding poverty alleviation achievements and comprehensively promoting rural revitalization," purchasing **CNY 123,500** worth of agricultural products from designated poverty alleviation counties in H1 2025[54](index=54&type=chunk) [Section V Significant Matters](index=16&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section details the company's fulfillment of commitments during and continuing into the reporting period, including those from controlling shareholders and actual controllers regarding horizontal competition and related party transactions, along with disclosures on significant related party transactions, progress and changes in raised fund utilization, and risk management measures - Controlling shareholder China Aerospace Science and Industry Defense Technology Research Institute and actual controller China Aerospace Science and Industry Corporation Limited have strictly fulfilled their commitments regarding resolving horizontal competition and related party transactions[56](index=56&type=chunk)[57](index=57&type=chunk)[58](index=58&type=chunk)[59](index=59&type=chunk)[60](index=60&type=chunk)[61](index=61&type=chunk) - The company signed a financial service agreement with Aerospace Science and Industry Finance Co., Ltd., providing deposit, loan, and settlement services, with deposit rates not lower than those of state-owned commercial banks and loan rates not higher than those of state-owned commercial banks[71](index=71&type=chunk) - As of June 30, 2025, the company's total deposit balance with Aerospace Science and Industry Finance Co., Ltd. was **CNY 571.31 million**, with no new loans[72](index=72&type=chunk) - The "Energy Storage Power Verification Capability Construction Project" has been terminated, and the remaining raised funds of **CNY 53.88 million** (including interest) will be permanently used to supplement working capital[82](index=82&type=chunk) - The scheduled usable date for the "AI-based Detection Equipment Development and System Platform R&D and Industrialization Project" has been postponed to April 2027[79](index=79&type=chunk) - Raised fund accounts have been cumulatively frozen for **CNY 42.01 million** by the court due to contract disputes[84](index=84&type=chunk) [Section VI Share Changes and Shareholder Information](index=30&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) This section discloses that the company's share capital structure remained unchanged during the reporting period and presents the total number of shareholders, top ten shareholders, and top ten unrestricted shareholders as of the end of the reporting period, revealing the company's equity structure and major shareholder composition - During the reporting period, the company's total share capital and share capital structure remained unchanged[87](index=87&type=chunk) - Total number of common shareholders at the end of the reporting period: **69,872** households[89](index=89&type=chunk) Top Ten Shareholders' Shareholding as of the End of the Reporting Period | Shareholder Name | Shares Held at Period-end (shares) | Percentage (%) | Share Status | Number (shares) | | :--- | :--- | :--- | :--- | :--- | | China Aerospace Science and Industry Defense Technology Research Institute | 141,150,722 | 30.13 | Unrestricted | 0 | | Chaoyang City Power Co., Ltd. | 39,449,467 | 8.42 | Pledged | 3,440,000 | | Beijing Institute of Computer Application and Simulation Technology | 10,245,120 | 2.19 | Unrestricted | 0 | | The 206th Institute of China Aerospace Science and Industry Corporation Second Academy | 9,284,640 | 1.98 | Unrestricted | 0 | | The 706th Institute of China Aerospace Science and Industry Corporation Second Academy | 4,282,240 | 0.91 | Unrestricted | 0 | | Wu Mingguang | 4,260,000 | 0.91 | Unrestricted | 0 | | Liu Jianwei | 3,509,100 | 0.75 | Unrestricted | 0 | | Zhang Shaoming | 3,212,200 | 0.69 | Unrestricted | 0 | | China Aerospace Science and Industry Corporation Limited | 2,915,199 | 0.62 | Unrestricted | 0 | | Hong Kong Securities Clearing Company Limited | 2,035,137 | 0.43 | Unrestricted | 0 | - China Aerospace Science and Industry Defense Technology Research Institute is the largest shareholder, holding **141,150,722 shares**, accounting for **30.13%**[91](index=91&type=chunk) - Chaoyang City Power Co., Ltd. holds **39,449,467 shares**, accounting for **8.42%**, of which **3,440,000 shares** are pledged[91](index=91&type=chunk) [Section VII Bond-Related Information](index=35&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) This section states that the company had no corporate bonds (including enterprise bonds) or non-financial enterprise debt financing instruments, nor any convertible corporate bonds during the reporting period, indicating no debt market financing - The company has no corporate bonds (including enterprise bonds) or non-financial enterprise debt financing instruments[97](index=97&type=chunk) - The company has no convertible corporate bonds[97](index=97&type=chunk) [Section VIII Financial Report](index=36&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) This section includes the company's unaudited consolidated and parent company financial statements, along with detailed notes to financial statement items, comprehensively reflecting the company's financial position, operating results, and cash flows at the end of the reporting period, and providing essential information on the company's background, accounting policies, and taxation - This semi-annual report is unaudited[99](index=99&type=chunk) - The financial report includes consolidated balance sheet, parent company balance sheet, consolidated income statement, parent company income statement, consolidated cash flow statement, parent company cash flow statement, consolidated statement of changes in equity, and parent company statement of changes in equity[99](index=99&type=chunk)[102](index=102&type=chunk)[106](index=106&type=chunk)[110](index=110&type=chunk)[114](index=114&type=chunk)[116](index=116&type=chunk)[119](index=119&type=chunk)[123](index=123&type=chunk) - The company primarily engages in the production and sale of medical device products, providing medical engineering services such as digital operating rooms; subsidiaries are involved in security technology system integration services, power equipment manufacturing, and R&D, production, and sales of infrared imaging systems[136](index=136&type=chunk)[137](index=137&type=chunk) - The company's financial statements are prepared on a going concern basis, and the company has the ability to continue as a going concern for 12 months from the end of the reporting period[138](index=138&type=chunk)[139](index=139&type=chunk) - The company and several subsidiaries are recognized as high-tech enterprises, enjoying a **15%** corporate income tax preferential rate[230](index=230&type=chunk) - The company's military-related scientific research projects are exempt from VAT as per regulations, and VAT on software products of the medical device branch is subject to immediate refund upon collection[231](index=231&type=chunk) [1. Audit Report](index=36&type=section&id=%E4%B8%80%E3%80%81%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) This section states that the company's semi-annual report is unaudited, consistent with the important notice - This semi-annual report is unaudited[99](index=99&type=chunk) [2. Financial Statements](index=36&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in equity for the first half of 2025, providing an overview of the company's financial position and operating results [Consolidated Balance Sheet](index=36&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of June 30, 2025, the company's consolidated total assets amounted to **CNY 3.67 billion**, total liabilities to **CNY 2.00 billion**, and total owners' equity to **CNY 1.67 billion** Consolidated Balance Sheet Key Data | Item | June 30, 2025 (CNY) | December 31, 2024 (CNY) | | :--- | :--- | :--- | | Total Assets | 3,674,362,149.00 | 3,721,891,711.89 | | Total Liabilities | 2,000,333,939.64 | 1,986,651,956.59 | | Total Owners' Equity | 1,674,028,209.36 | 1,735,239,755.30 | [Parent Company Balance Sheet](index=38&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of June 30, 2025, the parent company's total assets amounted to **CNY 2.26 billion**, total liabilities to **CNY 172 million**, and total owners' equity to **CNY 2.09 billion** Parent Company Balance Sheet Key Data | Item | June 30, 2025 (CNY) | December 31, 2024 (CNY) | | :--- | :--- | :--- | | Total Assets | 2,260,433,508.15 | 2,243,290,473.32 | | Total Liabilities | 172,422,893.42 | 158,258,434.49 | | Total Owners' Equity | 2,088,010,614.73 | 2,085,032,038.83 | [Consolidated Income Statement](index=40&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) In the first half of 2025, the company's consolidated total operating revenue was **CNY 358 million**, total profit was **CNY -58.22 million**, net profit was **CNY -60.67 million**, and net profit attributable to parent company shareholders was **CNY -55.59 million** Consolidated Income Statement Key Data | Item | 2025 H1 (CNY) | 2024 H1 (CNY) | | :--- | :--- | :--- | | Total Operating Revenue | 357,818,810.76 | 487,625,861.08 | | Total Operating Cost | 429,843,910.42 | 548,633,473.50 | | Total Profit | -58,221,603.02 | -52,521,596.08 | | Net Profit | -60,674,266.81 | -54,627,497.84 | | Net Profit Attributable to Parent Company Shareholders | -55,590,962.31 | -52,044,571.84 | | Basic Earnings Per Share (CNY/share) | -0.1186 | -0.1098 | [Parent Company Income Statement](index=42&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E5%88%A9%E6%B6%A6%E8%A1%A8) In the first half of 2025, the parent company's operating revenue was **CNY 10.43 million**, and net profit was **CNY 2.98 million**, a significant improvement from the loss in the same period last year Parent Company Income Statement Key Data | Item | 2025 H1 (CNY) | 2024 H1 (CNY) | | :--- | :--- | :--- | | Operating Revenue | 10,425,978.87 | 17,005,724.52 | | Operating Profit | 2,134,832.38 | -16,995,854.63 | | Total Profit | 2,978,575.90 | -16,964,569.12 | | Net Profit | 2,978,575.90 | -16,952,675.82 | [Consolidated Cash Flow Statement](index=44&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) In the first half of 2025, the company's net cash flow from operating activities was **CNY -133.91 million**, from investing activities was **CNY -6.75 million**, from financing activities was **CNY -30.83 million**, and the net increase in cash and cash equivalents was **CNY -171.48 million** Consolidated Cash Flow Statement Key Data | Item | 2025 H1 (CNY) | 2024 H1 (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -133,913,722.33 | -51,597,834.98 | | Net Cash Flow from Investing Activities | -6,746,518.35 | -40,002,018.65 | | Net Cash Flow from Financing Activities | -30,830,794.98 | -56,916,526.05 | | Net Increase in Cash and Cash Equivalents | -171,477,812.47 | -148,510,124.73 | | Cash and Cash Equivalents at Period-end | 640,467,532.38 | 809,049,970.23 | [Parent Company Cash Flow Statement](index=46&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) In the first half of 2025, the parent company's net cash flow from operating activities was **CNY -24.37 million**, from investing activities was **CNY 46.83 million**, from financing activities was **CNY -26.43 million**, and the net increase in cash and cash equivalents was **CNY -3.96 million** Parent Company Cash Flow Statement Key Data | Item | 2025 H1 (CNY) | 2024 H1 (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -24,365,710.53 | -54,012,452.78 | | Net Cash Flow from Investing Activities | 46,829,154.69 | -71,136.60 | | Net Cash Flow from Financing Activities | -26,431,363.68 | -49,479,223.15 | | Net Increase in Cash and Cash Equivalents | -3,956,171.91 | -103,568,885.57 | | Cash and Cash Equivalents at Period-end | 280,490,551.96 | 372,266,360.77 | [Consolidated Statement of Changes in Equity](index=48&type=section&id=%E5%90%88%E5%B9%B6%E6%89%80%E6%9C%89%E8%80%85%E6%9D%83%E7%9B%8A%E5%8F%98%E5%8A%A8%E8%A1%A8) In the first half of 2025, the company's consolidated total owners' equity decreased by **CNY 61.21 million**, primarily due to the net loss attributable to owners of the parent company Consolidated Statement of Changes in Equity Key Data | Item | 2025 H1 Period-end Balance (CNY) | 2024 H1 Period-end Balance (CNY) | | :--- | :--- | :--- | | Total Owners' Equity | 1,674,028,209.36 | 1,942,294,939.62 | | Total Owners' Equity Attributable to Parent Company | 1,553,229,358.56 | 1,803,122,674.02 | | Minority Interests | 120,798,850.80 | 139,172,265.60 | - The change amount (decrease) for the current period was **CNY -61.21 million**, mainly due to a total comprehensive income of **CNY -60.67 million**[120](index=120&type=chunk) [Parent Company Statement of Changes in Equity](index=51&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E6%89%80%E6%9C%89%E8%80%85%E6%9D%83%E7%9B%8A%E5%8F%98%E5%8A%A8%E8%A1%A8) In the first half of 2025, the parent company's total owners' equity increased by **CNY 2.98 million**, primarily due to an increase in total comprehensive income Parent Company Statement of Changes in Equity Key Data | Item | 2025 H1 Period-end Balance (CNY) | 2024 H1 Period-end Balance (CNY) | | :--- | :--- | :--- | | Total Owners' Equity | 2,088,010,614.73 | 2,160,478,187.34 | - The change amount (increase) for the current period was **CNY 2.98 million**, mainly due to a total comprehensive income of **CNY 2.98 million**[124](index=124&type=chunk) [3. Company Overview](index=54&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) This section outlines Beijing Aerospace Changfeng Co., Ltd.'s establishment history, share capital changes, main business segments, and organizational structure, emphasizing its background as a military asset listed company and its presence in military electronics, public safety, and high-end medical equipment - The company was established on December 25, 1985, and listed on the Shanghai Stock Exchange on April 25, 1994, with stock code 600855[127](index=127&type=chunk)[128](index=128&type=chunk) - The company's main businesses are divided into three segments: military electronics, public safety, and high-end medical equipment, covering urban security, border and coastal defense, medical devices, and other fields[136](index=136&type=chunk)[137](index=137&type=chunk) - The company's total share capital decreased from **474,192,298 shares** to **468,542,728 shares**, mainly due to the repurchase and cancellation of restricted shares[135](index=135&type=chunk) - The company's ultimate controlling party is China Aerospace Science and Industry Corporation Limited[132](index=132&type=chunk) [4. Basis of Financial Statement Preparation](index=56&type=section&id=%E5%9B%9B%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E7%9A%84%E7%BC%96%E5%88%B6%E5%9F%BA%E7%A1%80) This section clarifies that the company's financial statements are prepared on a going concern basis and confirms the company's ability to continue as a going concern for 12 months from the end of the reporting period, with no significant matters affecting this ability - The company's financial statements are prepared on a going concern basis[138](index=138&type=chunk) - The company has the ability to continue as a going concern for 12 months from the end of the reporting period, with no significant matters affecting this ability[139](index=139&type=chunk) [5. Significant Accounting Policies and Estimates](index=56&type=section&id=%E4%BA%94%E3%80%81%E9%87%8D%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%94%BF%E7%AD%96%E5%8F%8A%E4%BC%9A%E8%AE%A1%E4%BC%B0%E8%AE%A1) This section details the enterprise accounting standards, significant accounting policies, and estimates followed by the company in preparing its financial statements, covering financial instruments, inventories, revenue recognition, and asset impairment, along with materiality criteria and key assumptions - The company determines depreciation of fixed assets, amortization of intangible assets, capitalization conditions for R&D expenses, and revenue recognition policies based on its production and operation characteristics[140](index=140&type=chunk) - The company classifies financial assets into three categories: measured at amortized cost, measured at fair value through other comprehensive income, and measured at fair value through profit or loss[156](index=156&type=chunk) - The company consistently measures loss provisions for notes receivable, accounts receivable, and contract assets at an amount equal to the expected credit losses over their entire lifetime[164](index=164&type=chunk) - The company's revenue recognition principle is to recognize revenue when performance obligations in the contract are fulfilled, i.e., when the customer obtains control of the related goods or services[208](index=208&type=chunk) - The company distinguishes between research phase expenditures and development phase expenditures for internal R&D projects, capitalizing development phase expenditures when specific conditions are met[190](index=190&type=chunk) - The company assesses goodwill for impairment at least annually and estimates the recoverable amount of cash-generating units to which goodwill has been allocated[227](index=227&type=chunk) [6. Taxation](index=76&type=section&id=%E5%85%AD%E3%80%81%E7%A8%8E%E9%A1%B9) This section discloses the company's main tax categories and rates, and details the corporate income tax and VAT preferential policies enjoyed by the company and its subsidiaries, which positively impact the company's tax burden Main Tax Categories and Rates | Tax Category | Tax Basis | Tax Rate | | :--- | :--- | :--- | | Value-Added Tax | Taxable Revenue | 13%, 9%, 6% | | Urban Maintenance and Construction Tax | Amount of Turnover Tax Payable | 7%, 5% | | Corporate Income Tax | Taxable Income | 25% | - The company and several subsidiaries are recognized as high-tech enterprises, enjoying a **15%** corporate income tax preferential rate, valid for 3 years[230](index=230&type=chunk) - The company's military-related scientific research projects are exempt from VAT as per regulations; VAT on software products of the medical device branch is subject to immediate refund upon collection[231](index=231&type=chunk) [7. Notes to Consolidated Financial Statement Items](index=77&type=section&id=%E4%B8%83%E3%80%81%E5%90%88%E5%B9%B6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E9%A1%B9%E7%9B%AE%E6%B3%A8%E9%87%8A) This section provides detailed notes for each item in the consolidated financial statements, including monetary funds, notes receivable, accounts receivable, inventories, fixed assets, intangible assets, and liabilities, explaining their composition, changes, and related accounting treatments - Period-end monetary funds balance was **CNY 707.11 million**, including restricted funds of **CNY 66.64 million**, mainly comprising funds frozen due to litigation and acceptance bill deposits[234](index=234&type=chunk) - Notes receivable at period-end was **CNY 58.37 million**, a **52.05%** decrease from the beginning of the period, mainly due to matured acceptances and non-recourse commercial bill discounting[236](index=236&type=chunk)[37](index=37&type=chunk) - Accounts receivable at period-end was **CNY 1.02 billion**, with a total bad debt provision of **CNY 199.30 million**[249](index=249&type=chunk) - Inventories at period-end had a book value of **CNY 818.78 million**, with total provision for inventory depreciation and contract performance cost impairment of **CNY 65.90 million**[291](index=291&type=chunk) - Fixed assets at period-end had a book value of **CNY 367.12 million**, with accumulated depreciation of **CNY 236.02 million**[312](index=312&type=chunk)[313](index=313&type=chunk) - Intangible assets at period-end had a book value of **CNY 71.18 million**, with an increase of **CNY 1.38 million** in the current period[328](index=328&type=chunk) - Goodwill had a book original value of **CNY 81.66 million**, with full impairment provision already made[330](index=330&type=chunk)[332](index=332&type=chunk) - Contract liabilities at period-end were **CNY 358.28 million**, mainly comprising advance receipts for products and projects[354](index=354&type=chunk) - Employee compensation payable at period-end was **CNY 20.70 million**[356](index=356&type=chunk) - Undistributed profits at period-end were **CNY 3.77 million**, a decrease of **CNY 55.59 million** from the beginning of the period[385](index=385&type=chunk) - Current period credit impairment loss was **CNY 4.89 million**, and asset impairment loss was **CNY 1.89 million**[392](index=392&type=chunk)[394](index=394&type=chunk) - Net cash flow from operating activities was **CNY -133.91 million**, primarily due to increased operating payments for public safety and military electronics power businesses during the reporting period[35](index=35&type=chunk)[414](index=414&type=chunk) [Section IX Research and Development Expenses](index=125&type=section&id=%E5%85%AB%E3%80%81%E7%A0%94%E5%8F%91%E6%94%AF%E5%87%BA) This section discloses the company's R&D expenditures for the reporting period, including expensed and capitalized R&D, highlighting significant capitalized investment in the AI-integrated border and coastal defense detection equipment development project, reflecting the company's continuous commitment to technological innovation R&D Expenditure Details | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Employee Compensation | 20,671,134.98 | 21,213,737.11 | | Material Costs | 4,235,089.81 | 3,984,893.77 | | Travel Expenses | 1,206,732.13 | 807,974.96 | | Intangible Asset Amortization | 1,462,341.24 | 1,853,304.87 | | Fixed Asset Depreciation | 2,982,475.02 | 1,895,139.75 | | Entrusted R&D Fees | 73,113.21 | 2,801,572.67 | | Lease Fees | 1,510,942.14 | 1,510,942.14 | | Testing Fees | 266,444.62 | 378,922.21 | | Labor Fees | 559,472.65 | 374,506.07 | | Testing and Processing Fees | 569,904.38 | 671,181.53 | | Other | 3,117,867.81 | 2,928,261.33 | | Total | 36,655,517.99 | 38,420,436.41 | | Of which: Expensed R&D | 32,504,656.62 | 38,420,436.41 | | Capitalized R&D | 4,150,861.37 | - | - Total R&D expenditure for the current period was **CNY 36.66 million**, of which **CNY 32.50 million** was expensed R&D and **CNY 4.15 million** was capitalized R&D[424](index=424&type=chunk) - Capitalized R&D expenditures were primarily for the ZC230018 AI-integrated border and coastal defense detection equipment development and system platform project[426](index=426&type=chunk) [Section X Changes in Consolidation Scope](index=126&type=section&id=%E4%B9%9D%E3%80%81%E5%90%88%E5%B9%B6%E8%8C%83%E5%9B%B4%E7%9A%84%E5%8F%98%E6%9B%B4) This section states that the company experienced no changes in its consolidation scope during the reporting period due to non-same-control business combinations, same-control business combinations, reverse acquisitions, disposal of subsidiaries, or other reasons, indicating stable equity structure and business scope - The company had no non-same-control business combinations during the reporting period[426](index=426&type=chunk) - The company had no same-control business combinations during the reporting period[426](index=426&type=chunk) - The company had no reverse acquisitions or disposals of subsidiaries leading to loss of control during the reporting period[427](index=427&type=chunk) - The company had no other changes in consolidation scope during the reporting period[427](index=427&type=chunk) [Section XI Interests in Other Entities](index=127&type=section&id=%E5%8D%81%E3%80%81%E5%9C%A8%E5%85%B6%E4%BB%96%E4%B8%BB%E4%BD%93%E4%B8%AD%E7%9A%84%E6%9D%83%E7%9B%8A) This section lists the company's significant subsidiaries, including their main operating locations, registered capital, business nature, and shareholding percentages, and discloses key financial information for important non-wholly-owned subsidiaries, reflecting the company's control and investment in these entities Major Subsidiary Information | Subsidiary Name | Registered Capital (CNY) | Business Nature | Shareholding (%) | Acquisition Method | | :--- | :--- | :--- | :--- | :--- | | Beijing Aerospace Changfeng Technology Industry Group Co., Ltd. | 248,413,800.00 | Development, integration, and implementation of urban emergency and comprehensive security systems | 100.00 | Business combination under common control | | Beijing Changfeng Kewei Optoelectronic Technology Co., Ltd. | 193,902,091.33 | Design, development, production, and service of infrared detection, tracking, and imaging equipment | 95.16 | Investment establishment | | Aerospace Burke (Guangdong) Technology Co., Ltd. | 65,988,000.00 | R&D, production, and sales of UPS uninterruptible power supplies and EPS emergency power supplies | 55.45 | Business combination not under common control | | Aerospace Changfeng Chaoyang Power Co., Ltd. | 186,071,500.00 | Production and sales of integrated power supplies and module power supplies | 100.00 | Business combination under common control | | Aerospace Changfeng Medical Technology (Chengdu) Co., Ltd. | 140,000,000.00 | Production and sales of Class II medical devices; production and sales of Class III medical devices; construction engineering construction and design | 83.00 | Investment establishment | - Important non-wholly-owned subsidiaries include Beijing Changfeng Kewei Optoelectronic Technology Co., Ltd. (minority interest **4.84%**), Aerospace Burke (Guangdong) Technology Co., Ltd. (minority interest **44.55%**), and Aerospace Changfeng Medical Technology (Chengdu) Co., Ltd. (minority interest **17.00%**)[431](index=431&type=chunk) Key Financial Information of Important Non-Wholly-Owned Subsidiaries for the Current Period | Subsidiary Name | Operating Revenue (CNY) | Net Profit (CNY) | Total Comprehensive Income (CNY) | Cash Flow from Operating Activities (CNY) | | :--- | :--- | :--- | :--- | :--- | | Changfeng Kewei | 31,239,095.83 | -22,879,538.42 | -22,879,538.42 | 10,310,960.58 | | Aerospace Burke | 55,145,107.85 | -2,903,524.37 | -2,903,524.37 | 545,451.64 | | Changfeng Medical | 4,186,694.30 | -15,323,648.21 | -15,323,648.21 | -15,350,983.94 | [Section XII Government Grants](index=131&type=section&id=%E5%8D%81%E4%B8%80%E3%80%81%E6%94%BF%E5%BA%9C%E8%A1%A5%E5%8A%A9) This section discloses government grants recognized at the end of the reporting period based on receivable amounts and those recognized in profit or loss for the current period, demonstrating the contribution of government support to the company's operating results - Government grants recognized at the end of the reporting period based on receivable amounts totaled **CNY 3.91 million**[433](index=433&type=chunk) Government Grants Recognized in Profit or Loss for the Current Period | Type | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Asset-related | 808,999.98 | 505,426.44 | | Income-related | 4,322,986.74 | 2,879,206.21 | | Total | 5,131,986.72 | 3,384,632.65 | [Section XIII Risks Related to Financial Instruments](index=132&type=section&id=%E5%8D%81%E4%BA%8C%E3%80%81%E4%B8%8E%E9%87%91%E8%9E%8D%E5%B7%A5%E5%85%B7%E7%9B%B8%E5%85%B3%E7%9A%84%E9%A3%8E%E9%99%A9) This section describes the company's main financial instrument risks, including credit risk, liquidity risk, and market risk (interest rate risk, exchange rate risk), and outlines the policies and measures taken to manage these risks within defined limits - The company's main financial instrument risks are credit risk, liquidity risk, and market risk (including interest rate risk, exchange rate risk, and commodity price risk)[437](index=437&type=chunk) - The company manages credit risk by assessing customer creditworthiness, regularly monitoring credit records, and diversifying investment and business portfolios[439](index=439&type=chunk) - The company's maximum credit risk exposure is the carrying amount of each financial asset on the balance sheet[439](index=439&type=chunk) - As of June 30, 2025, the company's unused bank credit line was **CNY 1.72 billion**[442](index=442&type=chunk) - At period-end, the company's asset-liability ratio was **54.44%** (prior year-end: **53.38%**)[445](index=445&type=chunk) - The company's foreign currency assets and liabilities are not significant relative to its total assets and liabilities, so the exchange rate risk faced is not significant[444](index=444&type=chunk) [Section XIV Fair Value Disclosures](index=134&type=section&id=%E5%8D%81%E4%B8%89%E3%80%81%E5%85%AC%E5%85%81%E4%BB%B7%E5%80%BC%E7%9A%84%E6%8A%AB%E9%9C%B2) This section discloses the fair value of assets and liabilities measured at fair value at the end of the reporting period, primarily involving notes receivable financing, and explains their measurement hierarchy - Total assets continuously measured at fair value at period-end amounted to **CNY 2.07 million**[448](index=448&type=chunk) - This amount entirely consists of notes receivable financing, measured using Level 3 fair value inputs[448](index=448&type=chunk) [Section XV Related Parties and Related Party Transactions](index=136&type=section&id=%E5%8D%81%E5%9B%9B%E3%80%81%E5%85%B3%E8%81%94%E6%96%B9%E5%8F%8A%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) This section provides detailed information on the company's parent company, subsidiaries, and other related parties, as well as significant related party transactions during the reporting period, including purchases and sales of goods, provision and acceptance of services, related party leases, and related party fund movements, illustrating the business relationships between the company and its related parties - The company's parent company is China Aerospace Science and Industry Defense Technology Research Institute, which directly and indirectly holds **35.21%** of the company's equity[451](index=451&type=chunk) - The company's ultimate controlling party is China Aerospace Science and Industry Corporation Limited[451](index=451&type=chunk) - Total related party transactions for purchasing goods/receiving services in the current period amounted to **CNY 4.99 million**[63](index=63&type=chunk) - Total related party transactions for selling goods/providing services in the current period amounted to **CNY 55.14 million**[63](index=63&type=chunk) - Lease income recognized as lessor in the current period was **CNY 0.29 million**, and rent paid as lessee was **CNY 22.20 million**[461](index=461&type=chunk) - The company has financial business dealings with Aerospace Science and Industry Finance Co., Ltd.; as of June 30, 2025, the total deposit balance was **CNY 571.31 million**[463](index=463&type=chunk)[465](index=465&type=chunk) - Period-end receivables from related parties mainly include notes receivable, accounts receivable, and contract assets, with accounts receivable from China Aerospace Science and Industry Defense Technology Research Institute amounting to **CNY 48.30 million**[467](index=467&type=chunk) - Period-end payables to related parties mainly include contract liabilities, other payables, notes payable, and accounts payable, with accounts payable to China National Precision Machinery Import and Export Corporation amounting to **CNY 11.16 million**[471](index=471&type=chunk)[472](index=472&type=chunk) [Section XVI Share-Based Payments](index=150&type=section&id=%E5%8D%81%E4%BA%94%E3%80%81%E8%82%A1%E4%BB%BD%E6%94%AF%E4%BB%98) This section states that the company had no equity instruments, equity-settled or cash-settled share-based payment arrangements, share-based payment expenses, or modifications/terminations during the reporting period, indicating no implementation or changes to share-based payment plans - The company had no equity instruments, equity-settled or cash-settled share-based payment arrangements during the reporting period[473](index=473&type=chunk)[474](index=474&type=chunk) - There were no share-based payment expenses in the current period[474](index=474&type=chunk) - The company had no modifications or terminations of share-based payments during the reporting period[474](index=474&type=chunk) [Section XVII Commitments and Contingencies](index=151&type=section&id=%E5%8D%81%E5%85%AD%E3%80%81%E6%89%BF%E8%AF%BA%E5%8F%8A%E6%88%96%E6%9C%89%E4%BA%8B%E9%A1%B9) This section states that the company had no significant commitments or important contingent matters requiring disclosure during the reporting period, indicating no major outstanding commitments or potential obligations at the balance sheet date - The company has no significant commitments[474](index=474&type=chunk) - The company has no important contingent matters requiring disclosure[474](index=474&type=chunk) [Section XVIII Post-Balance Sheet Events](index=151&type=section&id=%E5%8D%81%E4%B8%83%E3%80%81%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8%E6%97%A5%E5%90%8E%E4%BA%8B%E9%A1%B9) This section states that the company had no significant non-adjusting events, profit distribution, or sales returns after the balance sheet date, indicating no material events affecting the financial statements between the balance sheet date and the report disclosure date - The company has no significant non-adjusting events[475](index=475&type=chunk) - The company has no profit distribution[475](index=475&type=chunk) - The company has no sales returns[475](index=475&type=chunk) [Section XIX Other Significant Matters](index=152&type=section&id=%E5%8D%81%E5%85%AB%E3%80%81%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section states that the company had no prior period accounting error corrections, significant debt restructurings, asset exchanges, annuity plans, or discontinued operations during the reporting period, and discloses that the company is divided into three reporting segments: public safety, military electronics, and high-end medical equipment, with their respective main business revenues - The company had no prior period accounting error corrections, significant debt restructurings, asset exchanges, annuity plans, or discontinued operations[475](index=475&type=chunk) - The company's operating businesses are divided into three reporting segments: public safety business, military electronics business, and high-end medical equipment business[475](index=475&type=chunk) Main Business Revenue by Reporting Segment | Item | Main Business Revenue (CNY) | | :--- | :--- | | High-end Medical Equipment Business | 5,237,355.16 | | Military Electronics | 222,461,520.95 | | Public Safety | 122,481,203.77 | | Total | 350,180,079.88 | [Section XX Notes to Major Items in Parent Company Financial Statements](index=153&type=section&id=%E5%8D%81%E4%B9%9D%E3%80%81%E6%AF%8D%E5%85%AC%E5%8F%B8%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E4%B8%BB%E8%A6%81%E9%A1%B9%E7%9B%AE%E6%B3%A8%E9%87%8A) This section provides detailed notes for major items in the parent company's financial statements, including accounts receivable, other receivables, long-term equity investments, operating revenue and cost, and investment income, reflecting the parent company's specific financial performance and asset-liability situation - Parent company accounts receivable at period-end had a book value of **CNY 9.71 million**, with a total bad debt provision of **CNY 16.29 million**[481](index=481&type=chunk)[486](index=486&type=chunk) - Parent company other receivables at period-end had a book value of **CNY 51.18 million**, with a total bad debt provision of **CNY 6.77 million**[489](index=489&type=chunk)[498](index=498&type=chunk) - Parent company long-term equity investments in subsidiaries at period-end had a book value of **CNY 1.65 billion**, with no impairment provision[506](index=506&type=chunk)[508](index=508&type=chunk) Parent Company Operating Revenue and Operating Cost | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Operating Revenue | 10,425,978.87 | 17,005,724.52 | | Operating Cost | 5,617,921.24 | 10,680,940.73 | - Parent company investment income for the current period was **CNY 41.90 million**, mainly from long-term equity investments accounted for using the cost method[514](index=514&type=chunk) [Section XXI Supplementary Information](index=163&type=section&id=%E4%BA%8C%E5%8D%81%E3%80%81%E8%A1%A5%E5%85%85%E8%B5%84%E6%96%99) This section provides supplementary financial information, including a detailed statement of non-recurring gains and losses for the current period, return on net assets, and earnings per share, further refining the company's financial performance and profitability - Total non-recurring gains and losses for the current period amounted to **CNY 5.57 million**[517](index=517&type=chunk) Return on Net Assets and Earnings Per Share | Profit for the Reporting Period | Weighted Average Return on Net Assets (%) | Earnings Per Share (CNY) | | :--- | :--- | :--- | | Net Profit Attributable to Common Shareholders of the Company | -3.52 | -0.1186 | | Net Profit Attributable to Common Shareholders of the Company after Deducting Non-recurring Gains and Losses | -3.87 | -0.1305 | - The company classifies software tax refunds, VAT input credit deductions, and individual income tax handling fee refunds as recurring gains and losses, as they are closely related to the company's normal operations and are continuously enjoyed[519](index=519&type=chunk)

Core Viewpoint - The company has announced a delay in the completion of its project "Research and Development of Detection Equipment and System Platform Based on Artificial Intelligence" from April 2026 to April 2027 due to various factors including market technology upgrades and macroeconomic conditions [1] Group 1 - The project delay is attributed to the need to integrate cutting-edge technologies such as artificial intelligence, low-altitude economy, and "anti-unmanned" technologies [1] - The company emphasizes that this delay will not have a substantial impact on the project's implementation or the company's normal operations [1] - The company will continue to adhere to regulatory requirements and enhance internal and external supervision of the use of raised funds to ensure their legal and effective utilization [1]

证券代码：600855 证券简称：航天长峰 公告编号：2025-044 北京航天长峰股份有限公司 十二届二十次董事会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京航天长峰股份有限公司（以下简称"航天长峰"或"公司"） 于 2025 年 8 月 12 日以书面形式发出通知，并于 2025 年 8 月 22 日上 午在航天长峰大厦八层 822 会议室以现场方式召开了十二届二十次 董事会会议，应到董事 9 人，实到董事 9 人。本次会议由董事长肖海 潮先生主持，会议程序符合《中华人民共和国公司法》和《公司章程》 的有关规定。与会董事认真审议了本次会议的议案，形成了如下决议： 一、审议通过了公司 2025 年半年度报告全文及摘要。 公司 2025 年半年度报告及摘要在提交董事会前已经董事会审计 委员会 2025 年第四次会议审议通过。 详见上海证券交易所网站 http://www.sse.com.cn。 此议案表决结果如下：9 票赞成，0 票弃权，0 票反对。 二、审议通过了公司《关于 2025 年半年度募集资金存 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年8月22日 (二)股东大会召开的地点：北京海淀区永定路甲51号航天长峰大楼八层822会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 本次股东大会，由公司董事长肖海潮先生主持，会议采用现场记名投票表决与网络投票表决相结合的方 式进行表决，会议召集、召开程序及表决方式符合《公司法》及《公司章程》的规定。 2、公司在任监事3人，出席2人，皮银林监事因其他工作原因无法出席； 3、董事会秘书王艳彬先生出席会议；部分高级管理人员列席了会议。 (一)非累积投票议案 1、议案名称：公司关于修订《公司章程》及《股东会议事规则》《董事会议事规则》的议案 审议结果：通过 表决情况： ■ 2、议案名称：公司关于取消监 ...

北京海润天睿律师事务所 关于北京航天长峰股份有限公司 2025 年第二次临时股东大会的法律意见书 中国·北京 北京市朝阳区建外大街甲 14 号广播大厦 5 层&9 层&10 层&13 层&17 层 电话（Tel）：86-10-65219696 传真（Fax）：86-10-88381869 股东大会法律意见书 北京海润天睿律师事务所 股东大会法律意见书 关于北京航天长峰股份有限公司 2025 年第二次临时股东大会的法律意见书 致：北京航天长峰股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受北京航天长峰股份有限 公司（以下简称"公司"）的委托，指派冯玫律师、张玉慧律师出席公司 2025 年第二次临时股东大会，并依据《中华人民共和国公司法》（以下简称"《公司 法》"）、《公司章程》及其他相关法律、法规和规范性文件的规定，就公司本 次股东大会的召集、召开程序、出席会议人员的资格、召集人资格、表决程序、 表决结果等有关事宜出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集、召开程序、出席会议人员的资格、召集 人资格、表决程序、表决结果发表意见，不对本次会议所审议 ...